than those aged 2 to 6 or 13 to 18 years. Patients with severe asthma, as defined by $6 pharmacy claims for short-acting b-agonists in the calendar year of the ED visit, were more likely to receive ICSs, to receive ICSs or leukotriene modifiers, to attend follow-up appointments, and to attend follow-up appointments and receive ICSs.
CONCLUSIONS. This study clearly demonstrates that most children in the South Carolina Medicaid population with asthma treated in the ED for an asthma exacerbation do not receive appropriate preventive care, including filling a prescription for an ICS and attending outpatient followup appointments.
REVIEWER COMMENTS.
As has been demonstrated previously, this study shows that the rate of follow-up and the use of asthma controller medications after an ED visit for an asthma exacerbation are quite poor. The authors were unable to determine if ED physicians were not prescribing controller medications, if patients were not having prescriptions filled, or if a combination of factors led to a lack of controller medication use. The Medicaid population frequently uses the ED for primary care-related issues, and this study shows that measures aimed at preventing ED visits for asthma exacerbations are not being addressed adequately. Authors of future studies may consider investigating the role of the ED physician in prescribing asthma controller medications and strategies for improving adherence in this patient population. To compare subjective and objective measurements of adherence to inhaled corticosteroids versus placebo and to determine if adherence to study medications modified treatment-related outcomes.
STUDY POPULATION. One hundred forty children aged 5 to 12 years who were diagnosed with mild or moderate asthma were enrolled from 3 of 8 sites from the Childhood Asthma Management Program (CAMP) study.
METHODS. This was a prospective study over a 4-year study period. The study population was categorized with mild or moderate asthma based on criteria established in the CAMP trial. Subjects were randomly assigned to receive either placebo, budesonide, or nedocromil twice daily over 4 years; those in the placebo and budesonide arms were included in this ancillary adherence report from 3 centers. Adherence measures were categorized as either self-reported or objective. Self-reported adherence consisted of daily diary entries by patient or caregiver that were reviewed at follow-up visits every 4 months. Objective adherence measures included counting the doses remaining in the Turbuhaler device (ie, doses dispensed).
RESULTS. Objective adherence measurements were significantly lower than self-reported adherence measurements. There was poor agreement between self-reported and objective measures of adherence, with 75% of participants demonstrating ,80% adherence by objective measurements, whereas only 5.8% of self-reported adherence values were ,80%. 
